All Biomarkers articles – Page 6
-
ArticleBeyond ELISA: the future of biomarker validation
The era of precision medicine demands more rigorous biomarker validation methods. While ELISA has long been the gold standard, advanced technologies such as LC-MS/MS and Meso Scale Discovery (MSD) offer superior precision, sensitivity and efficiency. Here, Prasad Lakshmanan Selvaraj, Director of Technical Review at Sannova, explains that by embracing these ...
-
ArticleHarnessing the CD24/Siglec-10 pathway: immunotherapy innovation
Renowned immunologist Dr Yang Liu shares his insights into the preclinical studies behind the development of drug candidates targeting the CD24/Siglec-10 pathway. He discusses the technical and regulatory hurdles of antibody development, how these therapies compare to existing immunotherapies, and the potential for personalised cancer treatment through biomarker development.
-
News
Discovery of a signalling pathway that activates desire to exercise
The study highlights the possible therapeutic significance of targeting the pathway for treating obesity and metabolic disease.
-
News
Revolutionary blood test identifies patients with brain injuries
Orlando Health Orlando Regional Medical Center is the first hospital in the world to use the blood test.
-
NewsIdentifying biomarkers for progressive supranuclear palsy
Protein biomarkers in spinal fluid linked to PSP could enable earlier diagnosis and treatment for this neurological disorder.
-
NewsNew biomarker for asymptomatic stages of Alzheimer’s disease
Researchers identified miR-519a-3p as a biomarker that could enable early diagnosis and treatment of neurodegenerative diseases.
-
NewsNew first trimester screening algorithm for preeclampsia
The screening model combines maternal history, ultrasound data and several tests for blood markers to enable personalised treatment.
-
WhitepaperPoster: Assays for PRMT5, MLL4, METTL3/14, & NSP14
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
-
ArticleBiomarker identification in the realm of rare diseases
In this Q&A, Debiopharm’s Principal Scientist Dr Luke Piggott defines the critical requirement of biomarkers for identifying rare diseases. He illuminates how AI-enhanced approaches are accelerating the drug discovery process, particularly regarding clinical trial enrolment, and the breakthroughs he hopes to see in the future.
-
NewsNew methodologies to find microbiome biomarkers
Confounder control and quantitative profiling revealed misleading associations between microbial markers and colorectal cancer development.
-
ArticleUncovering the genetic and cellular impacts of smoking
Epigenetic data assessing the effects of smoking on DNA methylation could serve as biomarkers of exposure effects.
-
NewsElevated TMAO levels predict future risk of CKD
Elevated levels of trimethylamine N-oxide levels were a stronger indicator of CKD risk than the well-known risk factors.
-
NewsImproved understanding of the liver fibrosis process
Scientists have examined gene activity in mice models, noting important indicators of liver disease severity which may be used as therapeutic strategies.
-
NewsNew insights into viral-related myocarditis
Understanding heart changes at the molecular level during early infection with adenovirus could enable identification of those at higher risk of arrhythmia.
-
NewsSerum biomarkers for COVID-19 identified
Proteins regulating plasminogen-plasmin levels can be used to identify patients at risk of progressing to a severe stage of COVID-19.
-
NewsUsing omic data to develop and validate biomarkers of ageing
Researchers highlight the need for considering biomarkers alongside other health outcomes, as well as the need for omic data standardisation.
-
NewsIdentification of an immune biomarker for liver cancer
New immunotherapies may be developed for patients with HCC associated with steatotic liver disease, with TREM1 suggested as a target.
-
NewsMulti-omic approach classifies biomarkers for paediatric sepsis
Researchers have discovered potential biomarkers to identify paediatric sepsis progression stage, enabling more targeted treatment.
-
ArticleInvestigating the intratumoural microbiome in young-onset CRC patients
New insights about young-onset CRC tumour-related bacteria could lead to new diagnostic markers and therapeutic targets.
-
WhitepaperApplication note: In situ identification of cancer stem cell niches (HCC)
This app note explores a groundbreaking multiplex immunodetection approach to identify cancer stem cell niches within hepatocellular carcinoma (HCC).